WenxinLee
2021-09-21
Nice
BioNTech SE stock jumped 4% in morning trading<blockquote>BioNTech SE股价早盘上涨4%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":860767592,"tweetId":"860767592","gmtCreate":1632215849816,"gmtModify":1632802020830,"author":{"id":4087695368272510,"idStr":"4087695368272510","authorId":4087695368272510,"authorIdStr":"4087695368272510","name":"WenxinLee","avatar":"https://static.tigerbbs.com/bad37890ba35bb7193190c5c08ea56fb","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/860767592","repostId":1189685868,"repostType":4,"repost":{"id":"1189685868","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1631714905,"share":"https://www.laohu8.com/m/news/1189685868?lang=zh_CN&edition=full","pubTime":"2021-09-15 22:08","market":"us","language":"en","title":"BioNTech SE stock jumped 4% in morning trading<blockquote>BioNTech SE股价早盘上涨4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1189685868","media":"Tiger Newspress","summary":"BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore wanin","content":"<p>BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares rose 0.7%.</p><p><blockquote>BioNTech SE股价早盘上涨4%，辉瑞表示疫苗加强注射可以恢复减弱的免疫力。辉瑞股价上涨0.7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/fb4c307ca1b61c145bfb12a955ecf588\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Pfizer Inc. said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.</p><p><blockquote>辉瑞公司表示，来自美国和以色列的数据表明，其Covid-19疫苗的效力随着时间的推移而减弱，加强剂量在抵御病毒和新变种方面是安全有效的。</blockquote></p><p> The company detailed the data in a presentation it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.</p><p><blockquote>该公司将在周五向美国食品和药物管理局外部顾问会议提交的演示文稿中详细介绍了这些数据。预计该小组将就更多美国人是否应该接受加强注射提出建议。</blockquote></p><p> “Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s BioNTech SE to make the shots.</p><p><blockquote>辉瑞在FDA网站上发布的演示文稿中表示：“来自以色列和美国的真实数据表明，较早接种疫苗的个体突破性感染率上升得更快。”这家制药巨头正在与德国BioNTech SE合作进行注射。</blockquote></p><p> The decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.</p><p><blockquote>辉瑞研究人员在演示中表示，有效性下降“主要是由于疫苗免疫反应随着时间的推移而减弱”，而不是德尔塔变异毒株。</blockquote></p><p> <b>Unpublished Data</b></p><p><blockquote><b>未公布数据</b></blockquote></p><p> According to a meeting agenda the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.</p><p><blockquote>根据FDA在其网站上发布的会议议程，除了辉瑞的演讲外，周五的小组讨论还将包括疾病控制和预防中心、FDA工作人员以及来自以色列和英国的研究人员的演讲。</blockquote></p><p> The Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.</p><p><blockquote>根据议程，以色列官员将介绍该国关于针对感染和严重疾病的加强保护的数据，布里斯托尔大学的医学统计学教授将介绍现实世界疫苗有效性的数据。</blockquote></p><p> While its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.</p><p><blockquote>辉瑞表示，虽然其疫苗继续在美国提供针对住院和严重疾病的强大保护，但来自以色列和其他地方的数据表明，针对感染的效力降低后，针对严重疾病的效力可能会降低，特别是在脆弱的老年人中。</blockquote></p><p> Early unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.</p><p><blockquote>根据辉瑞公司的文件，来自以色列健康维护组织的早期未发表的数据表明，第三次加强剂量在德尔塔变异毒株占主导地位的地区非常有效。辉瑞表示，从加强注射后至少一周开始，给60岁以上的人注射第三剂疫苗对新冠病毒检测呈阳性的有效率为86%。</blockquote></p><p> Pfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.</p><p><blockquote>辉瑞还详细介绍了对300多人进行加强注射的最后阶段试验的免疫反应结果，显示第三剂疫苗提高了血液抗体水平。第三次注射后一个月，保护性抗体水平是第二次注射后一个月的三倍多。</blockquote></p><p> No new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.</p><p><blockquote>根据辉瑞的报告，在最后阶段的研究中，从与加强剂相关的安全数据中没有发现新的意外副作用。辉瑞表示，基于以色列和美国疫情的相似性，有必要在第二剂疫苗接种六个月后考虑加强剂量。</blockquote></p><p> <b>Signs of Friction</b></p><p><blockquote><b>摩擦迹象</b></blockquote></p><p> Marion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.</p><p><blockquote>FDA最近表示将于今年晚些时候辞职的两名高级疫苗官员之一马里恩·格鲁伯(Marion Gruber)也计划发表讲话。格鲁伯是本周早些时候《柳叶刀》上一篇文章的合著者，该文章认为大多数人还没有必要注射加强针。两名长期担任该机构工作人员的离职是拜登助推器计划摩擦的潜在迹象。</blockquote></p><p> The FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.</p><p><blockquote>FDA尚未发布其关于加强剂数据的工作人员报告。该机构的文件通常在小组会议开始前48小时发布。</blockquote></p><p> The FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.</p><p><blockquote>发言人艾莉森·亨特(Alison Hunt)表示，FDA正在尽快在产品最终确定并可用后全天发布产品。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech SE stock jumped 4% in morning trading<blockquote>BioNTech SE股价早盘上涨4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech SE stock jumped 4% in morning trading<blockquote>BioNTech SE股价早盘上涨4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-15 22:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares rose 0.7%.</p><p><blockquote>BioNTech SE股价早盘上涨4%，辉瑞表示疫苗加强注射可以恢复减弱的免疫力。辉瑞股价上涨0.7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/fb4c307ca1b61c145bfb12a955ecf588\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Pfizer Inc. said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.</p><p><blockquote>辉瑞公司表示，来自美国和以色列的数据表明，其Covid-19疫苗的效力随着时间的推移而减弱，加强剂量在抵御病毒和新变种方面是安全有效的。</blockquote></p><p> The company detailed the data in a presentation it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.</p><p><blockquote>该公司将在周五向美国食品和药物管理局外部顾问会议提交的演示文稿中详细介绍了这些数据。预计该小组将就更多美国人是否应该接受加强注射提出建议。</blockquote></p><p> “Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s BioNTech SE to make the shots.</p><p><blockquote>辉瑞在FDA网站上发布的演示文稿中表示：“来自以色列和美国的真实数据表明，较早接种疫苗的个体突破性感染率上升得更快。”这家制药巨头正在与德国BioNTech SE合作进行注射。</blockquote></p><p> The decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.</p><p><blockquote>辉瑞研究人员在演示中表示，有效性下降“主要是由于疫苗免疫反应随着时间的推移而减弱”，而不是德尔塔变异毒株。</blockquote></p><p> <b>Unpublished Data</b></p><p><blockquote><b>未公布数据</b></blockquote></p><p> According to a meeting agenda the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.</p><p><blockquote>根据FDA在其网站上发布的会议议程，除了辉瑞的演讲外，周五的小组讨论还将包括疾病控制和预防中心、FDA工作人员以及来自以色列和英国的研究人员的演讲。</blockquote></p><p> The Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.</p><p><blockquote>根据议程，以色列官员将介绍该国关于针对感染和严重疾病的加强保护的数据，布里斯托尔大学的医学统计学教授将介绍现实世界疫苗有效性的数据。</blockquote></p><p> While its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.</p><p><blockquote>辉瑞表示，虽然其疫苗继续在美国提供针对住院和严重疾病的强大保护，但来自以色列和其他地方的数据表明，针对感染的效力降低后，针对严重疾病的效力可能会降低，特别是在脆弱的老年人中。</blockquote></p><p> Early unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.</p><p><blockquote>根据辉瑞公司的文件，来自以色列健康维护组织的早期未发表的数据表明，第三次加强剂量在德尔塔变异毒株占主导地位的地区非常有效。辉瑞表示，从加强注射后至少一周开始，给60岁以上的人注射第三剂疫苗对新冠病毒检测呈阳性的有效率为86%。</blockquote></p><p> Pfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.</p><p><blockquote>辉瑞还详细介绍了对300多人进行加强注射的最后阶段试验的免疫反应结果，显示第三剂疫苗提高了血液抗体水平。第三次注射后一个月，保护性抗体水平是第二次注射后一个月的三倍多。</blockquote></p><p> No new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.</p><p><blockquote>根据辉瑞的报告，在最后阶段的研究中，从与加强剂相关的安全数据中没有发现新的意外副作用。辉瑞表示，基于以色列和美国疫情的相似性，有必要在第二剂疫苗接种六个月后考虑加强剂量。</blockquote></p><p> <b>Signs of Friction</b></p><p><blockquote><b>摩擦迹象</b></blockquote></p><p> Marion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.</p><p><blockquote>FDA最近表示将于今年晚些时候辞职的两名高级疫苗官员之一马里恩·格鲁伯(Marion Gruber)也计划发表讲话。格鲁伯是本周早些时候《柳叶刀》上一篇文章的合著者，该文章认为大多数人还没有必要注射加强针。两名长期担任该机构工作人员的离职是拜登助推器计划摩擦的潜在迹象。</blockquote></p><p> The FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.</p><p><blockquote>FDA尚未发布其关于加强剂数据的工作人员报告。该机构的文件通常在小组会议开始前48小时发布。</blockquote></p><p> The FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.</p><p><blockquote>发言人艾莉森·亨特(Alison Hunt)表示，FDA正在尽快在产品最终确定并可用后全天发布产品。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189685868","content_text":"BioNTech SE stock jumped 4% in morning trading as Pfizer said booster shots of vaccine restore waning Immunity.Pfizer shares rose 0.7%.\n\nPfizer Inc. said that data from the U.S. and Israel suggest that the efficacy of its Covid-19 vaccine wanes over time, and that a booster dose was safe and effective at warding off the virus and new variants.\nThe company detailed the data in a presentation it will deliver to a meeting of outside advisers to the Food and Drug Administration on Friday. The panel is expected to make recommendations for whether more Americans should receive booster shots.\n“Real-world data from Israel and the United States suggest that rates of breakthrough infections are rising faster in individuals who were vaccinated earlier,” Pfizer said in its presentation, which was posted on the FDA website. The drug giant is partnering with Germany’s BioNTech SE to make the shots.\nThe decrease in effectiveness is “primarily due to waning of vaccine immune responses over time,” rather than the delta variant, Pfizer researchers said in the presentation.\nUnpublished Data\nAccording to a meeting agenda the FDA posted on its website, in addition to the Pfizer presentation, the Friday panel will include presentations from the Centers for Disease Control and Prevention, FDA staff and researchers from Israel and the U.K.\nThe Israel officials will present data from that country on booster protection against infections and severe disease, according to the agenda, and a professor of medical statistics from the University of Bristol will present data on real-world vaccine effectiveness.\nWhile its vaccine continues to provide strong protection against hospitalizations and severe disease in the U.S., Pfizer said, data from Israel and elsewhere suggests that reduction in efficacy against infection may be followed by reduced effectiveness against severe disease, especially among vulnerable elderly people.\nEarly unpublished data from an Israeli health maintenance organization suggest that a third booster dose is highly effective in areas where the delta variant is dominant, according to the Pfizer document. Giving a third dose to people more than 60 years old was associated with 86% effectiveness against testing positive for Covid starting at least a week after the booster, Pfizer said.\nPfizer also detailed immune response results from a final-stage trial of booster shots in over 300 people, showing that a third dose bolstered blood antibody levels. One month after the third dose, levels of the protective antibodies were more than triple what they had been a month after the second shot.\nNo new unexpected side effects were identified from safety data associated with boosters in the final-stage study, according to the Pfizer report. Consideration of a booster dose six months after a second dose of its shot is warranted, based on similarities between the outbreaks in Israel and the U.S., Pfizer said.\nSigns of Friction\nMarion Gruber, one of two top vaccine officials who FDA recently said will step down later this year, is also scheduled to speak. Gruber was co-author of an article in The Lancet earlier this week arguing that booster shots weren’t yet necessary for most people. The departures of the two longtime agency staff are a potential sign of friction over the Biden booster plan.\nThe FDA hasn’t yet posted its staff report on the booster data. The agency’s documents are typically released 48 hours before the start of a panel meeting.\nThe FDA is working as quickly as possible to post the items throughout the day as they are finalized and available, spokesperson Alison Hunt said.","news_type":1,"symbols_score_info":{"PFE":0.9,"BNTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2106,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/860767592"}
精彩评论